MGD is the primary cause of dry eye worldwide
Over 30 million Americans have dry eye. If you include the number of persons who live with or socialize with a dry eye sufferer, the number of affected Americans easily surpasses 75 million.
Meibomian Gland Dysfunction (MGD) is the most common cause of dry eye and has certainly been the most challenging to treat. Traditional therapies have failed to consistently provide effective results leading to ongoing suffering and frustration for patients and physicians alike.
Current procedures to clear glands of obstructions and promote oil secretion do not treat the underlying problem of periductal fibrosis (scar tissue) surrounding Meibomian Glands and thereby overlook the long-term problem.
In fact, common therapies for dry eye, particularly heat combined with pressure, may only serve to further inflame affected eyelids and result in greater discomfort and loss of function. Without first clearing away the scar tissue, the gland remains blocked.
Meibomian Gland Probing (MGP) is an effective proven method to clear glands of constricting periductal fibroses (scar tissue) allowing glands to again deliver essential meibum & relieving dry eye symptoms.
Guide to the Maskin® Probing Protocol
Probing Meibomian Glands to return function and relieve dry eye symptoms is an essential precursor to further treatment.
First, identify gland health and atrophy. Then, restore the integrity of the intraductal space through Meibomian Gland Probing. Finally, proceed with treatment for underlying and co-morbid factors of dry eye and MGD.
MEIBOMIAN GLAND EXAMINATION TO IDENTIFY ATROPHY:
Use meibography data to determine number of functional glands and identify atrophied glands. Video meibography is recommended to prevent misleading artifact in images.
